Oto Takahiho, Rosenfeldt Franklin, Rowland Michael, Pick Adrian, Rabinov Marc, Preovolos Arthur, Snell Gregory, Williams Trevor, Esmore Donald
Heart and Lung Transplant Unit, The Alfred Hospital, Monash University Medical School, Melbourne, VIC, Australia.
Ann Thorac Surg. 2004 Oct;78(4):1230-5. doi: 10.1016/j.athoracsur.2004.03.095.
Severe pulmonary graft failure (PGF) is the most common cause of death within the first 30 days after lung transplantation. Extracorporeal membrane oxygenation (ECMO) may provide lifesaving temporary support; however, its longer-term efficacy is controversial.
We reviewed the use of ECMO for severe PGF after lung transplantation, and compared the outcomes between our early (1990 to 1999) and recent (2000 to 2003) experience utilizing improved initiation timing, oxygenator technology, and surgical technique.
Ten transplant recipients from a total of 481 (2.1%) were managed for PGF on ECMO by a multidisciplinary team at The Alfred Hospital. Four single-lung, 3 bilateral single-lung, and 3 heart-lung recipients were supported for a mean of 96 hours (range 14 to 212 hours). In the early group (operation from 1990 to 1999, n = 4) ECMO was initiated 21 days (range 7 to 40 days) after lung transplantation and in the recent group (operation from 2000 to 2003, n = 6) after 0 to 2 days (p = 0.01). Radial-arterial blood gas analysis 12 hours after initiation of ECMO showed significantly better oxygenation in the recent group (341 +/- 90 mm Hg) than in the early group (90 +/- 23 mm Hg, p = 0.03). Four deaths occurred as a result of bleeding (two in each group). In the early group only 1 patient was weaned from ECMO but died. In the recent group 3 were successfully weaned and were discharged from the intensive care unit; of these patients, 2 were discharged from hospital.
Extracorporeal membrane oxygenation results have improved with advances in oxygenator technology and surgical techniques. The procedure can allow resolution of early PGF after lung transplantation.
严重肺移植失败(PGF)是肺移植术后30天内最常见的死亡原因。体外膜肺氧合(ECMO)可提供挽救生命的临时支持;然而,其长期疗效存在争议。
我们回顾了肺移植术后ECMO用于严重PGF的情况,并比较了我们早期(1990年至1999年)和近期(2000年至2003年)利用改进的启动时机、氧合器技术和手术技术的经验的结果。
阿尔弗雷德医院的一个多学科团队对481例患者中的10例(2.1%)因PGF接受了ECMO治疗。4名单肺移植、3例双侧单肺移植和3例心肺联合移植受者接受了平均96小时(范围14至212小时)的支持。在早期组(1990年至1999年手术,n = 4),ECMO在肺移植术后21天(范围7至40天)启动,而在近期组(2000年至2003年手术,n = 6)在0至2天启动(p = 0.01)。ECMO启动12小时后的桡动脉血气分析显示,近期组(341±90 mmHg)的氧合明显优于早期组(90±23 mmHg,p = 0.03)。4例患者因出血死亡(每组2例)。早期组只有1例患者成功脱离ECMO但死亡。近期组有3例成功脱离ECMO并从重症监护病房出院;其中2例出院。
随着氧合器技术和手术技术的进步,体外膜肺氧合的结果有所改善。该方法可使肺移植术后早期PGF得到缓解。